Skip to main content
. 2014 Apr 11;28(5):538–545. doi: 10.1038/eye.2014.64

Table 1. Group characteristics.

  Group 1 (bevacizumab to ranibizumab) Group 2 (ranibizumab to bevacizumab) P-value
Number of subjects 114 24  
Women 77 (68%) 17 (71%) 0.753
Age (years) 77.8±8.2 77.5±7.5 0.675
Visual acuity, time of switch (logMAR) 0.52±0.3 0.41±0.3 0.049
Macular thickness, time of switch (μm) 418±166 340±131 0.037
Number of injections before switch 9.8±4.6 8.9±4.0 0.316
Better eye treated 53 (46%) 9 (38%) 0.421